Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,341 to 4,360 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Alteplase Active Control Group vs Tenecteplase Treatment Group: serious adverse events | 115 of 736 116 of 732 | -0.2 points -4.0 to 3.5 | 1,468 | NCT04915729 A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity |
| Zishen Yutai Pill Group vs Placebo Group: Biochemical Pregnancy Rate | 232 of 734 195 of 733 | 5.0 points 0.4 to 9.6 | 1,467 | NCT03703700 The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET |
| Zishen Yutai Pill Group vs Placebo Group: Live Birth Rate | 171 of 734 139 of 733 | 4.3 points 0.2 to 8.5 | 1,467 | NCT03703700 The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET |
| Zishen Yutai Pill Group vs Placebo Group: Clinical Pregnancy Rate | 216 of 734 177 of 733 | 5.3 points 0.7 to 9.8 | 1,467 | NCT03703700 The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET |
| Zishen Yutai Pill Group vs Placebo Group: serious adverse events | 22 of 734 18 of 733 | 0.5 points -1.2 to 2.3 | 1,467 | NCT03703700 The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET |
| Standard Influenza Surveillance Period vs Point-of-care Molecular Testing and Treatment of Influenza Period: Feasibility of Implementation of Point-of-care Molecular Testing and Treatment of Influenza in Shelters | 266 of 701 308 of 764 | -2.4 points -7.3 to 2.6 | 1,465 | NCT04141917 Test-and-treat for Influenza in Homeless Shelters |
| Everolimus vs Placebo: serious adverse events | 154 of 740 68 of 723 | 11.4 points 7.8 to 15.0 | 1,463 | NCT01120249 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery |
| V419 vs Control: serious adverse events | 58 of 980 32 of 483 | -0.7 points -3.6 to 1.8 | 1,463 | NCT01337167 Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) |
| Intervention vs Usual Care: Adherence to Medication | 341 of 681 250 of 782 | 18.1 points 13.1 to 23.0 | 1,463 | NCT02790463 Virtual Gout Clinic |
| Intervention vs Usual Care: sUA < 6.0 mg/dl at 1 Year | 204 of 681 117 of 782 | 15.0 points 10.7 to 19.2 | 1,463 | NCT02790463 Virtual Gout Clinic |
| Intervention vs Usual Care: serious adverse events | 1 of 681 1 of 782 | 0.0 points -0.6 to 0.7 | 1,463 | NCT02790463 Virtual Gout Clinic |
| Caduet vs Usual Care: serious adverse events | 51 of 779 22 of 682 | 3.3 points 1.1 to 5.6 | 1,461 | NCT00407537 Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors |
| Short Storage vs Standard Issue: serious adverse events | 80 of 728 84 of 733 | -0.5 points -3.7 to 2.8 | 1,461 | NCT01977547 Age of Blood in Children in Pediatric Intensive Care Units |
| Trastuzumab vs Trastuzumab Emtansine: Number of Participants With AEs and SAEs Leading to Death | 0 of 720 1 of 740 | -0.1 points -0.8 to 0.4 | 1,460 | NCT01772472 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) |
| Trastuzumab vs Trastuzumab Emtansine: Number of Participants Who Discontinued Treatment Due to AEs | 15 of 720 134 of 740 | -16.0 points -19.1 to -13.1 | 1,460 | NCT01772472 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) |
| Trastuzumab vs Trastuzumab Emtansine: serious adverse events | 58 of 720 94 of 740 | -4.6 points -7.8 to -1.5 | 1,460 | NCT01772472 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) |
| Short Storage vs Standard Issue: Nosocomial Infection | 24 of 728 23 of 732 | 0.2 points -1.7 to 2.0 | 1,460 | NCT01977547 Age of Blood in Children in Pediatric Intensive Care Units |
| Short Storage vs Standard Issue: Number of Participants With New or Progressive Multiple Organ Dysfunction Syndrome (NPMODS) | 147 of 728 133 of 732 | 2.0 points -2.0 to 6.1 | 1,460 | NCT01977547 Age of Blood in Children in Pediatric Intensive Care Units |
| STS101 5.2 mg vs STS101 Placebo: serious adverse events | 3 of 731 0 of 729 | 0.4 points -0.2 to 1.2 | 1,460 | NCT04940390 A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine |
| Depression - Immediate PGx Testing vs Depression - Delayed PGx Testing: deaths from any cause | 1 of 727 2 of 733 | -0.1 points -0.9 to 0.5 | 1,460 | NCT05966155 A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Depression Trial) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=218"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=218
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04915729-sae",
"title": "Alteplase Active Control Group vs Tenecteplase Treatment Group: serious adverse events",
"summary": "115 of 736 against 116 of 732; risk difference -0.2 points, 95% interval -4.0 to 3.5; NCT04915729, A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity",
"record": "/library/comparisons/NCT04915729-sae",
"nct_id": "NCT04915729",
"kind": "serious-adverse-events",
"participants": 1468,
"risk_difference": {
"value": -0.0022199453551912662,
"lower": -0.03955811188387835,
"upper": 0.03509973161904432
},
"group_1": "115 of 736",
"group_2": "116 of 732",
"difference": "-0.2 points",
"interval": "-4.0 to 3.5",
"trial_title": "A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity"
},
{
"id": "NCT03703700-1484b4d9",
"title": "Zishen Yutai Pill Group vs Placebo Group: Biochemical Pregnancy Rate",
"summary": "232 of 734 against 195 of 733; risk difference 5.0 points, 95% interval 0.4 to 9.6; NCT03703700, The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET",
"record": "/library/comparisons/NCT03703700-1484b4d9",
"nct_id": "NCT03703700",
"kind": "outcome",
"participants": 1467,
"risk_difference": {
"value": 0.05004628063536437,
"lower": 0.0035505346609978894,
"upper": 0.09624823095947349
},
"group_1": "232 of 734",
"group_2": "195 of 733",
"difference": "5.0 points",
"interval": "0.4 to 9.6",
"trial_title": "The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=219",
"request_id": "OubA-VZyTRzcLby7"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant